The earnings call highlighted significant progress in partnerships, financial stability, and R&D developments, particularly with the MSD partnership and a grant from the Gates Foundation. However, there are challenges due to regulatory and market uncertainties, and limited disclosure on clinical data was noted.

Company Guidance -

Q3 2025

During Evaxion's Q2 2025 conference call, significant guidance was provided regarding their R&D and financial outlook. The company is progressing well with its R&D pipeline, including the EVX-01 Phase II trial for advanced melanoma, with 2-year clinical outcome data set to be presented at the ESMO Congress in October. They have expanded their pipeline with the addition of EVX-B4, aimed at developing a vaccine against Group A Streptococcus, and received a grant from the Gates Foundation for a polio vaccine project. Financially, Evaxion has cash reserves of $14.7 million, projected to fund operations until mid-2026. They have also strengthened their equity by $4.1 million through a debt-to-equity conversion with the European Investment Bank. The company remains focused on business development, with ongoing partnership discussions, and anticipates key milestones in the second half of 2025.

Partnership with MSD on Track

Significant achievements with the partnership with MSD, with a potential option exercise in the second half of 2025.

Financial Stability

Cash at hand until mid-2026 and conversion of a loan from the European Investment Bank into equity, increasing equity by USD 4.1 million.

R&D Progress

Key R&D events include EVX-01 2-year clinical efficacy data accepted for presentation at ESMO Congress 2025 and the initiation of the EVX-B4 program.

Gates Foundation Grant

Received a grant from the Gates Foundation for a polio vaccine project, enhancing the platform's exposure and potential future collaborations.

Positive Financial Performance

Operating loss reduced to $4.3 million in Q2 2025 from $4.6 million in the same period last year, with cash reserves projected to last until mid-2026.

Evaxion Biotech (EVAX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EVAX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.58 / -	-0.2	―	―	―
Aug 14, 2025	2025 (Q2)	-0.58 / -0.02	-0.6	96.67% (+0.58)	―
May 27, 2025	2025 (Q1)	- / -0.01	0.15	-106.67% (-0.16)	―
Apr 01, 2025	2024 (Q4)	-0.70 / -0.01	0.15	-106.67% (-0.16)	―
Oct 31, 2024	2024 (Q3)	-1.57 / -0.20	-10.5	98.10% (+10.30)	―
Aug 14, 2024	2024 (Q2)	-1.27 / -0.60	-10.5	94.29% (+9.90)	―
May 28, 2024	2024 (Q1)	-5.47 / 0.15	-12	101.25% (+12.15)	―	―
Mar 27, 2024	2023 (Q4)	-8.00 / -8.00	-14.5	44.83% (+6.50)	―	―
Dec 19, 2023	2023 (Q3)	-9.50 / -10.50	-12	12.50% (+1.50)	―	―
Aug 18, 2023	2023 (Q2)	-10.75 / -10.50	-10	-5.00% (-0.50)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EVAX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$3.04	$2.86	-5.92%
May 27, 2025	$1.88	$2.36	+25.53%
Apr 01, 2025	$1.85	$1.66	-10.27%
Oct 31, 2024	$13.80	$13.35	-3.26%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Evaxion Biotech (EVAX) report earnings?

Evaxion Biotech (EVAX) is schdueled to report earning on Nov 11, 2025, Before Open (Not Confirmed).

What is Evaxion Biotech (EVAX) earnings time?

Evaxion Biotech (EVAX) earnings time is at Nov 11, 2025, Before Open (Not Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EVAX EPS forecast?

EVAX EPS forecast for the fiscal quarter 2025 (Q3) is -0.59.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing